Objective
To examine the behaviour of the major inhibitors of fibrinolysis (PAI‐1 and PAI‐2) in normal pregnancy and pregnancy complicated by either pre‐eclampsia or hydatidiform mole.
Design
Prospective study.
Setting
Antenatal Clinic and Maternity Hospital.
Subjects
Eleven women with established pre‐eclampsia and eleven women, matched by age, parity, and duration of pregnancy who were undergoing uncomplicated pregnancy. Two women having surgery for hydatidiform mole.
Main outcome measure
Plasma levels of PAI‐1 and PAI‐2 antigens determined by sensitive specific ELISA. Functional identification of PAI‐2 by nondenaturing gel electrophoresis with overlay zymography.
Results
In pre‐eclampsia PAI‐2 antigen was significantly lower than in normal pregnancy (105.3 ± 34.9 versues 187.1 ± 67.9 ng/ml; P<0.001). In contrast PAI‐1 antigen was significantly higher in pre‐eclampsia than in normal pregnancy (170.7 ± 71.2 versus 113.8 ± 35.6 ng/ml; P<0.05). In consequence the ratio of PAI‐1/PAI‐2 increased markedly in pre‐eclampsia (2.5 versus 0.6). No PAI‐2 was detected in plasma of women with hydatidiform moles.
Conclusions
PAI‐2 levels fell significantly in pre‐eclampsia probably as a result of decreased placental mass or function. The raised PAI‐1 level in pre‐eclampsia may reflect a response to hypertension or renal damage that is not specific to pregnancy or may reflect altered placental function. The use of the ratio of PAI‐1/PAI‐2 assists in separating normal from abnormal pregnancies.
This study shows that pretreatment with phalloidin, before the administration of dextran, abolishes the lowering of P(if) and edema formation, which is detected after i.v. injection of dextran alone.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.